You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma
|
|---|---|
| Published in |
BMC Cancer, December 2013
|
| DOI | 10.1186/1471-2407-13-561 |
| Pubmed ID | |
| Authors |
Sanne EJ Wolf, Christina Meenken, Annette C Moll, John B Haanen, Michiel S van der Heijden |
| Abstract |
Vemurafenib, an inhibitor of genetically activated BRAF, is now commonly prescribed for metastatic melanoma harboring a BRAF mutation. Reports on side effects have focused on cutaneous complications. We here present a case of a severe pan-uveitis associated with vemurafenib use. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 2 | 9% |
| Switzerland | 1 | 4% |
| Brazil | 1 | 4% |
| Unknown | 19 | 83% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 6 | 26% |
| Researcher | 6 | 26% |
| Student > Ph. D. Student | 3 | 13% |
| Student > Bachelor | 2 | 9% |
| Student > Doctoral Student | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 4 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 65% |
| Agricultural and Biological Sciences | 2 | 9% |
| Unknown | 6 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 December 2013.
All research outputs
#17,704,678
of 22,733,113 outputs
Outputs from BMC Cancer
#4,960
of 8,270 outputs
Outputs of similar age
#223,667
of 307,131 outputs
Outputs of similar age from BMC Cancer
#61
of 106 outputs
Altmetric has tracked 22,733,113 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,270 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 34th percentile – i.e., 34% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 307,131 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 106 others from the same source and published within six weeks on either side of this one. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.